File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker

TitleEnhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
Authors
Issue Date2010
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
Citation
Annals Of Surgical Oncology, 2010, v. 17 n. 9, p. 2518-2525 How to Cite?
AbstractBackground: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP 20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. © 2010 Society of Surgical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/124045
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 1.037
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China30331160411
Hong Kong Research Grants CouncilN_HKU718/03
Natural Science Foundation of Beijing7042032
Funding Information:

This study was jointly supported by the Scheme of National Natural Science Foundation of China (30331160411), the Hong Kong Research Grants Council (N_HKU718/03), and the Natural Science Foundation of Beijing (7042032). We acknowledge Dr. CK Hui for his clinical expertise and Professor QY He for his expert opinions and advices on protein identification in serum samples.

References

 

DC FieldValueLanguage
dc.contributor.authorChen, Len_HK
dc.contributor.authorHo, DWYen_HK
dc.contributor.authorLee, NPYen_HK
dc.contributor.authorSun, Sen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorWong, KFen_HK
dc.contributor.authorYi, Xen_HK
dc.contributor.authorLau, GKen_HK
dc.contributor.authorNg, EWYen_HK
dc.contributor.authorPoon, TCWen_HK
dc.contributor.authorLai, PBSen_HK
dc.contributor.authorCai, Zen_HK
dc.contributor.authorPeng, Jen_HK
dc.contributor.authorLeng, Xen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorLuk, JMen_HK
dc.date.accessioned2010-10-19T04:35:45Z-
dc.date.available2010-10-19T04:35:45Z-
dc.date.issued2010en_HK
dc.identifier.citationAnnals Of Surgical Oncology, 2010, v. 17 n. 9, p. 2518-2525en_HK
dc.identifier.issn1068-9265en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124045-
dc.description.abstractBackground: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP 20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. © 2010 Society of Surgical Oncology.en_HK
dc.languageengen_HK
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.orgen_HK
dc.relation.ispartofAnnals of Surgical Oncologyen_HK
dc.rightsThe original publication is available at www.springerlink.comen_HK
dc.rightsThe Author(s)en_US
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en_US
dc.subject.meshLiver Neoplasms - blood - diagnosis-
dc.subject.meshProteome - analysis-
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods-
dc.subject.meshTumor Markers, Biological - blood-
dc.subject.meshalpha-Fetoproteins - metabolism-
dc.titleEnhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein markeren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1068-9265&volume=17&issue=9&spage=2518&epage=2525&date=2010&atitle=Enhanced+detection+of+early+hepatocellular+carcinoma+by+serum+SELDI-TOF+proteomic+signature+combined+with+alpha-fetoprotein+marker-
dc.identifier.emailLee, NPY: nikkilee@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityLee, NPY=rp00263en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1245/s10434-010-1038-8en_HK
dc.identifier.pmid20354800-
dc.identifier.pmcidPMC2924503-
dc.identifier.scopuseid_2-s2.0-77956345377en_HK
dc.identifier.hkuros182516-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956345377&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue9en_HK
dc.identifier.spage2518en_HK
dc.identifier.epage2525en_HK
dc.identifier.eissn1534-4681-
dc.identifier.isiWOS:000281858600035-
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 01 Dec 2010-
dc.identifier.scopusauthoridChen, L=7409441990en_HK
dc.identifier.scopusauthoridHo, DWY=7402971906en_HK
dc.identifier.scopusauthoridLee, NPY=7402722690en_HK
dc.identifier.scopusauthoridSun, S=21740136100en_HK
dc.identifier.scopusauthoridLam, B=7102023588en_HK
dc.identifier.scopusauthoridWong, KF=35081410800en_HK
dc.identifier.scopusauthoridYi, X=55138104500en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK
dc.identifier.scopusauthoridNg, EWY=36126827200en_HK
dc.identifier.scopusauthoridPoon, TCW=7006151710en_HK
dc.identifier.scopusauthoridLai, PBS=7202946421en_HK
dc.identifier.scopusauthoridCai, Z=7402904946en_HK
dc.identifier.scopusauthoridPeng, J=7401958598en_HK
dc.identifier.scopusauthoridLeng, X=7102492468en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.issnl1068-9265-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats